In the preceding three months, 7 analysts have released ratings for Kymera Therapeutics (NASDAQ:KYMR), presenting a wide array of perspectives from bullish to bearish.

The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $50.29, a high estimate of $65.00, and a low estimate of $36.00. Witnessing a positive shift, the current average has risen by 26.36% from the previous average price target of $39.80.

Analyzing Analyst Ratings: A Detailed Breakdown

The standing...